Synopsis of recent research by authors named "Aleix Llorac Moix"
- Aleix Llorac Moix's research primarily focuses on the cost-effectiveness and budget impact of anticoagulant medications in Spain, assessing non-vitamin K antagonist oral anticoagulants (NOACs) such as rivaroxaban, dabigatran, and apixaban against traditional vitamin K antagonists (VKAs) for stroke prevention in patients with non-valvular atrial fibrillation.
- A key study utilized a Markov model to analyze real-world data, demonstrating the cost-effectiveness of NOACs over VKAs for stroke prevention, which has significant implications for healthcare decision-making in Spain.
- Another significant contribution examined the budget impact of using rivaroxaban for preventing thromboembolic events following total hip or knee replacements, highlighting its advantages in efficacy and safety compared to standard enoxaparin regimens in surgical settings.
